Microneedles for controlled and sustained intraocular drug delivery

用于控制和持续眼内药物递送的微针

阅读:1

Abstract

Microneedles (MNs) have emerged as a promising technology for minimally invasive drug delivery, offering significant advantages in the treatment of ocular diseases. These miniaturized needles enable precise, localized drug delivery directly into specific tissues of the eye, such as the cornea, sclera, vitreous, or retina, while minimizing pain and discomfort. MNs can be fabricated from various biocompatible materials, including metals, silicon, and biodegradable polymers, making them highly adaptable to various clinical applications. Recent advancements in MN design include the integration of 3D printing technologies to create highly customized geometries for improved drug delivery precision, the use of smart materials that enable stimuli-responsive and sustained drug release, and the development of hybrid microneedles combining different polymers to enhance both mechanical strength and controlled drug release. These innovations have established MNs as a superior alternative to traditional methods like eye drops or intravitreal injections, which often face issues of limited bioavailability and patient compliance. This review summarizes the current state of research on MN-based ocular drug delivery, focusing on material developments, fabrication methods, drug release mechanisms, and implantation techniques. Future directions for MN technology in ophthalmology are also discussed, highlighting its potential to improve treatment outcomes for complex ocular diseases.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。